<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641963</url>
  </required_header>
  <id_info>
    <org_study_id>aICP Stroke</org_study_id>
    <nct_id>NCT03641963</nct_id>
  </id_info>
  <brief_title>aICP Measurement in Patients With Cerebral Artery Infarction / aICP MCA Infarction</brief_title>
  <acronym>aICPStroke</acronym>
  <official_title>Non-invasive Absolute Intracranial Pressure Measurement in Patients With Malignant Middle Cerebral Artery Infarction for Determination of Timing to Decompressive Craniectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Aarau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Space-occupying, malignant middle cerebral artery (M-MCA) infarctions are still one of the&#xD;
      most devastating forms of ischemic stroke, with a mortality of up to 80% in untreated&#xD;
      patients. It is reported that early hemicraniectomy leads to a substantial decrease in&#xD;
      mortality at 6 and 12 months and is likely to improve functional outcome. Thus, this study&#xD;
      investigates if non-invasive intracranial pressure (ICP) measuring could represent an&#xD;
      objective value to determine the time point to indicate decompressive craniectomy surgery.&#xD;
&#xD;
      However, there are still important questions about the individual indication for&#xD;
      decompressive surgery. In consideration of a variable clinical course (some patients develop&#xD;
      fatal brain edema early, whereas other patients do not show severe brain swelling for several&#xD;
      days), achieving a way to measure, control and predict malignant brain edema formation would&#xD;
      be of extremely important value.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Space-occupying, malignant middle cerebral artery (M-MCA) infarctions are still one of the&#xD;
      most devastating forms of ischemic stroke, with a mortality of up to 80% in untreated&#xD;
      patients.&#xD;
&#xD;
      Actually, M-MCA infarctions constitute between 1% to 10% of all supratentorial ischemic&#xD;
      strokes, with a yearly incidence about 10-20/100.000 people. The etiology of malignant MCA&#xD;
      infarctions is mostly due to thrombosis or embolic occlusion of either the internal carotid&#xD;
      artery or the proximal MCA. The term M-MCA is referred to a severe MCA syndrome with typical&#xD;
      clinical symptoms (hemiparesis to hemiplegia, severe sensory deficits, head and eye&#xD;
      deviation, hemi-inattention, and, if the dominant hemisphere is involved, global aphasia),&#xD;
      following a uniform clinical course (progressive deterioration of conscious within the first&#xD;
      24-48 h), and ending in herniation. An early diagnosis is essential and depends on CT&#xD;
      (Computed Tomography) and MRI (Magnetic Resonance Imaging) to aid the prediction of a&#xD;
      malignant course, but, until today there is no clear consensus to define and predict&#xD;
      radiologically a malignant evolution in early phases.&#xD;
&#xD;
      Several pharmacological strategies have been proposed but the efficacy of these approaches&#xD;
      has not been supported by adequate evidence from clinical trials and, until recently,&#xD;
      treatment of malignant MCA infarctions has been a major unmet need.&#xD;
&#xD;
      Over the past 10 years, results from randomised controlled trials (RCT) (HAMLET, DECIMAL and&#xD;
      DESTINY) and their pooled analyses have provided evidence that an early hemicraniectomy leads&#xD;
      to a substantial decrease in mortality at 6 and 12 months and is likely to improve functional&#xD;
      outcome. However, there are still important questions about the individual indication for&#xD;
      decompressive surgery. In consideration of a variable clinical course (some patients develop&#xD;
      fatal brain edema early, whereas other patients do not show severe brain swelling for several&#xD;
      days), achieving a way to measure, control and predict malignant brain edema formation would&#xD;
      be of extremely important value.&#xD;
&#xD;
      In this way, the ICP measuring could represent an objective value to determine in every&#xD;
      patient the time point to indicate decompressive craniectomy surgery, and also could allow us&#xD;
      to find a correlation between the size of the infarction and periinfarction edema. Therefore&#xD;
      the optimal timing of surgical intervention can be defined and all the medical treatment&#xD;
      adjusted.&#xD;
&#xD;
      Currently, ICP can be measured and registered only using invasive techniques. The two ICP&#xD;
      measurement methods available - intraventricular and intraparenchymal - require both a&#xD;
      neurosurgical procedure, in order to implant the catheter and probes within the brain. Thus,&#xD;
      these measures include themselves a risk for the subject, and both infections and&#xD;
      intracranial bleedings are regular albeit not frequent complications. In addition, invasive&#xD;
      recording of ICP requires neurosurgical expertise and intensive care unit (ICU) facilities.&#xD;
      Therefore ICP measurement so far, is not a standard of care in stroke units.&#xD;
&#xD;
      A reliable, accurate and precise non-invasive method to measure ICP would be of considerable&#xD;
      clinical value, enabling ICP measurement without neurosurgical expertise and ICU facilities.&#xD;
      Moreover, it would save the patients from the complication risks associated with invasive&#xD;
      measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Safety questions on patients with glaucoma are in discussion by our IRB&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased intracranial pressure</measure>
    <time_frame>24 months</time_frame>
    <description>The primary outcome is the non-invasive, absolute intra-cranial pressure (ICP) in M-MCA patients before decompressive surgery, as determined by the &quot;non-invasive ICP absolute value meter&quot; in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of ICP, neuroimaging and transcranial color Doppler</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation between non-invasive measured ICP and clinical and neuroimaging findings and standard transcranial color Doppler</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Stroke patients with ICP measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vittamed 205 Non-invasive intracranial pressure (ICP) meter</intervention_name>
    <description>Non-Invasive intracranial pressure measurement</description>
    <arm_group_label>Stroke patients with ICP measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with an ischemic stroke in the internal carotid artery or middle cerebral&#xD;
             artery territory at risk of a malignant MCA evolution, defined based on clinical&#xD;
             presentation, clinical course (showing a progressive deterioration of conscious within&#xD;
             the first 24-48 h), and neuroradiological findings.&#xD;
&#xD;
          -  Age: â‰¥ 18 years at admission&#xD;
&#xD;
          -  Informed consent of the patient or consent of patient's next of kin (plus consent of&#xD;
             an independent physician)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with wounds, scars including the front orbital region.&#xD;
&#xD;
          -  Patients with any known ocular condition that may be worsened by sustained eye&#xD;
             pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Fandino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Aarau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau AG</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Aarau</investigator_affiliation>
    <investigator_full_name>Javier Fandino, MD</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

